Advanced Search

 

Study ID Status Title Patient Level Data
CR9106327 Completed An Open-Label Study to Investigate the Excretion and Metabolic Disposition of a Single, Oral Dose of [14C]-SB-751689 (a calcium-sensing receptor antagonist) in Healthy Male Subjects and Healthy Postmenopausal Female Subjects
CR9106339 Completed An open-label study to evaluate the effects of repeat dosing of esomeprazole on the pharmacokinetics of SB-751689 in healthy adult subjects
CR9106341 Completed An open-label, randomized, five period crossover study to estimate the relative bioavailability of five formulations of 400 mg ronacaleret (a calcium-sensing receptor antagonist) administered as a single oral dose to healthy postmenopausal females.
CR9107262 Completed A two-part dose-rising study to evaluate the safety, tolerability and pharmacokinetics of SB-751689 when administered as an oral formulation at supratherapeutic dose levels in healthy adult subjects.
CR9108122 Completed An exploratory, open label, multicenter parallel group study to evaluate the effects of single and repeat dosing of SB-751689 (400 mg or 100 mg) or rhPTH(1-34) on the fractional renal excretion of calcium and phosphate in healthy postmenopausal females.
CR9108307 Completed An open-label, randomized, five period crossover study to estimate the relative bioavailability of five formulations of 400mg SB-751689 (a calcium-sensing receptor antagonist) administered as a single oral dose to healthy postmenopausal females
CR9108914 Terminated A Proof-of-Concept Study Of SB-751689 In Men And Post-menopausal Women With A Fractured Distal Radius Study Listed on ClinicalStudyDataRequest.com
CR9108963 Terminated Study CR9108963: A 12-month, randomized, double-blind, parallel-group, placebo and active-controlled dose-range finding study of the efficacy and safety of SB-751689 in post-menopausal women with osteoporosis Study Listed on ClinicalStudyDataRequest.com
CR9108985 Completed An Open-Label, Partially Randomized, Interaction Study to Evaluate the Effects of SB-751689 on the Pharmacokinetics of Rosuvastatin and Atorvastatin or the Effects of Ketoconazole on the Pharmacokinetics of SB-751689 in Healthy Postmenopausal Female Subjects
CRB100706 Terminated A study to identify a transcriptomic profile indicative of cycle AMP pathway activation in the lung
CRH103002 Terminated An open-label, repeat-dose, single-sequence study to investigate the effects of once-daily repeat oral administration of GW876008 125mg on the pharmacokinetics of the combined oral contraceptive in female volunteers
CRH103004 Completed An open-label, parallel group, single session study comparing the pharmacokinetics of a single oral dose of GW876008 administered to healthy volunteer smokers and healthy volunteer non-smokers.
CRH103152 Completed An open-label, single-sequence study to evaluate the potential CYP 3A4 pharmacokinetic interaction of GW876008 in healthy subjects
CRH103390 Completed Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD)
CRH104150 Completed A randomized, placebo-controlled, double-dummy, four-way crossover design study to investigate the changes of fMRI BOLD activation induced by emotional activation paradigms following single doses of GW876008 and lorazepam (comparator) in healthy subjects.
CRH108571 Completed Double-blind, randomized, placebo and Alprazolam-controlled three-period crossover incomplete block design study to compare putative anxiolytic-like fRMI activity of GW876008 and GSK561679 after single-dose administration in subjects with Social Anxiety Disorder (SAD)
CRI103143 Completed A Phase IIa, single-centre, randomised, placebo-controlled, double-blind, three-period crossover study investigating the effects on gut autonomic responses of single administrations of either 20 mg or 200 mg GW876008, a CRF1 antagonist, to adult patients with irritable bowel syndrome
CRI103147 Completed A Phase IIa experimental medicine study assessing alterations in Regional Cerebral Blood Flow by functional magnetic resonance imaging (fMRI) in female IBS patients and healthy controls following single doses of GW876008, a corticotrophin releasing factor 1 receptor antagonist (CRF1-RA)
CRI105626 Completed A randomised, double-blind, placebo-controlled, crossover study to evaluate efficacy and safety of the CRF1 receptor antagonist GW876008 in patients with Irritable Bowel Syndrome
CRI109244 Withdrawn A double-blind, randomised, placebo-controlled, three-period crossover study to investigate the pharmacodynamic effect of two CRF-1 antagonists GSK561679 and GW876008 on meal induced cortisol responses in patients with IBS.
CRR110198 Terminated A Double-Blind, Parallel, Randomized, Placebo-Controlled, Single and Repeat Dose Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GSK706769 in Healthy Male and Female Subjects
CRR110744 Completed Phase I, open label drug-drug interaction study in healthy volunteers to evaluate the effect of KALETRA (lopinavir-ritonavir) on GSK706769 pharmacokinetics and to evaluate the pharmacokinetics of a new oral formulation of GSK706769
CRR111382 Completed A Double-Blind, Randomized, Placebo-Controlled, Repeat Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK706769 in Healthy Male and Female Subjects
CRS 105510 Completed A randomised, placebo-controlled, double-dummy, crossover design study to investigate the changes of fMRI BOLD activation induced by emotional activation paradigms following single doses of GSK561679 and lorazepam (comparator) in healthy subjects
CRS105511 Completed Placebo-Controlled, Randomized, Blinded, Double-Dummy, Crossover study to Investigate the Attenuation of ACTH Activation Induced by Metyrapone with a single dose of GSK561679 or Alprazolam in Healthy Volunteers

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.